Mouse Monoclonal CD191 Antibody

The CD191 antibody targets CCR1 (C-C chemokine receptor type 1), a G protein-coupled receptor (GPCR) belonging to the β-chemokine receptor family. CCR1 is expressed on immune cells, including monocytes, neutrophils, T cells, and dendritic cells, and plays a critical role in mediating chemotaxis and inflammatory responses. It binds multiple ligands, such as CCL3 (MIP-1α), CCL5 (RANTES), and CCL7 (MCP-3), activating signaling pathways that regulate cell migration, immune activation, and tissue homeostasis. CCR1 is implicated in various inflammatory and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, as well as in cancer metastasis and HIV pathogenesis. Antibodies against CD191 are widely used in research to study CCR1 expression, ligand-receptor interactions, and its functional role in disease models. They enable applications like flow cytometry, immunohistochemistry, and neutralization assays. Therapeutic targeting of CCR1 with monoclonal antibodies or small-molecule inhibitors has been explored to modulate inflammatory pathways, though clinical success remains limited. CD191 antibodies also serve as tools to validate CCR1 as a biomarker in disease progression or therapeutic response, highlighting their dual utility in basic research and drug development.